In patients with inflammatory bowel disease, neither biologics nor small molecule targeted therapies increase the risk for major adverse cardiac events, according to the largest study to address this question. Biologics were associated with a reduced risk for both major adverse cardiac events (MACE) and venous thromboembolism (VTE) relative to no biologics. Small molecule therapies, such as Janus kinase (JAK) inhibitors, were associated with a neutral effect. “Hopefully these data comfort us,” said investigator Miguel Regueiro, MD, the chair of the Digestive Disease & Surgery Institute at Cleveland Clinic, in Ohio. Dr. Regueiro also expressed hope these data might change…
Author: Abhay Panchal
The article from Cureus focuses on the advancements in early cancer detection, exploring the roles of biomarkers, circulating DNA (ctDNA), and innovative technological approaches. Key points from the article include: Importance of Early Cancer Detection: Early detection of cancer is crucial for improving patient prognoses and increasing the chances of a full recovery. Screening plays a significant role in detecting cancer at early stages, potentially before symptoms arise and ideally before metastasis. Challenges and Opportunities in Early Detection: The article discusses the challenges in early cancer detection, such as the need for identifying consequential illnesses that might cause significant morbidity…
The Yahoo Finance article discusses predictions for how artificial intelligence (AI) will impact various aspects of healthcare in 2024. The article includes insights from experts in the field, highlighting several key areas where AI is expected to make significant contributions: AI in Healthcare Administration: AI is expected to play a major role in streamlining administrative tasks in healthcare. Companies like Microsoft, Amazon, and Google are developing next-generation tech to relieve doctors and medical staff from burdensome administrative duties. Health insurers are also exploring AI to automate the claims process. Impact on Productivity and Costs: AI could boost productivity, reduce costs,…
Medtronic has expanded its partnership with Cosmo Intelligent Medical Devices to further develop and capitalize on the GI Genius intelligent endoscopy module, a significant move in integrating artificial intelligence (AI) into endoscopic care. Key points of this partnership include: This partnership represents a significant step in the advancement of AI in endoscopic care, aiming to improve patient outcomes and healthcare efficiency through innovative technology.
The Healio article discusses the efforts of the American Society for Gastrointestinal Endoscopy’s (ASGE) diversity, equity, and inclusion (DEI) subcommittee to address disparities and lack of equitable care in gastroenterology. The subcommittee aims to bring important DEI issues to the forefront and offer solutions to mitigate existing disparities in the field. Key highlights from the article include: Impact of Disparities on Providers and Patients: Disparities in gastroenterology affect job satisfaction, retention, and education for providers, as well as patient access to care and their sense of acceptance. ASGE’s DEI Initiatives: ASGE’s DEI subcommittee has been working to address these issues…
Ayble Health, a digital health platform for patients with chronic gastrointestinal (GI) conditions, has announced a partnership with Commure Engage, an AI-powered care coordination platform. This collaboration aims to improve patient experiences and outcomes in GI care while reducing hospital admissions. Key aspects of this partnership include: Addressing the GI Specialist Shortage: The growing GI patient population faces challenges due to a critical shortage of GI specialists, dietitians, and psychologists. Ayble acts as a “specialty care referral in a box” for providers, offering an alternative solution to this shortage. Integration with Commure Engage: Ayble will be integrated within the Commure…
A study from the Perelman School of Medicine at the University of Pennsylvania found that liver cancer screening rates among patients with cirrhosis nearly doubled when they were mailed a signed order from their specialist. This study, published in Hepatology Communications, did not find any significant difference in screening completion rates when a $20 incentive was added to the mailed orders. Key points from the study include: Increased Screening Rates: When patients with cirrhosis were mailed an order to get an abdominal ultrasound, about 55% completed their screening within six months of receiving the letter. This rate was significantly higher…
Patients with cirrhosis are especially susceptible to liver cancer, but mailing screening orders directly to patients helped nudge them toward getting ultrasounds.
The Becker’s ASC Review article highlights the top five gastroenterology stories of 2023, capturing significant events and developments in the field. These stories include: These stories reflect the diverse range of topics and issues that have shaped the field of gastroenterology in 2023, from personal tragedies and policy changes to recognitions of excellence in medical care and research.
The Fierce Healthcare article discusses the outlook for 2024 regarding the use of GLP-1 medications, particularly in the context of weight loss and the sustainability of results after discontinuing the drug. Key points from the article include: Popularity of GLP-1 Medications: GLP-1 medications, such as Eli Lilly’s Zepbound and Mounjaro (tirzepatide), were a major topic in healthcare in 2023. These drugs have shown significant results in weight loss, with a study in JAMA Network indicating an average 20% mean body weight loss in overweight or obese adults using tirzepatide. Weight Regain Concerns: A major concern highlighted is the weight regain…